-+ 0.00%
-+ 0.00%
-+ 0.00%

Tyra Biosciences Announces Phase 2 SURF302 Study of Dabogratinib in FGFR3-Altered Non-Muscle Invasive Bladder Cancer

Reuters·02/23/2026 22:30:17

Please log in to view news